Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT - Morningstar

Vaderis announces positive results from its HHT clinical trial with VAD044, showing favorable safety, tolerability, and efficacy in key disease manifestations. Ongoing OLE data at 6 months confirm consistent safety and improvements in bleeding parameters.